Differentiated Thyroid CancerHoTNCT05604963
Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
A study testing Total Thyroidectomy and Hemithyroidectomy in people with Differentiated Thyroid Cancer, run by University College, London at 33 sites in United Kingdom.
Trial summary
This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer. Patients will be identified via oncology multidisciplinary team meetings. There will be two sources of patients in the trial, with the same histological diagnoses and prognosis (i.e. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Differentiated Thyroid Cancer
- What is being tested?
- Total Thyroidectomy and Hemithyroidectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 456 participants
- Where
- 33 sitesUnited Kingdom
- Study dates
- 14 Feb 2022to 31 Jul 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Aged 16 or over
- Papillary thyroid cancer:
- pT1b-2 (≤4cm) irrespective of molecular genetic markers
- R0 resection (clinically excised but microscopic R1 resected tumours at discretion of the local MDT)
- cN0 or pN0, pNX \& pN1a (≤5 foci, no extranodal spread)
- Confined to thyroid or minimal extrathyroidal extension
Show all 21Show fewer
- No higher risk histological variants on morphology (small foci allowed at the discretion of the local MDT)
- No angioinvasion NB. PTC is still eligible where microscopic invasion of endothelial lined small capillary vascular spaces and lymphatic channels are present. It becomes ineligible in the rare instances when there is definite invasion of a larger vascular structure such as a vein with smooth muscle in its wall.
- Encapsulated FVPTC with capsular invasion only
- Micro-PTC (≤1cm)
- multifocal
- unifocal with pN1a (≤5 foci; no extranodal spread)
- Follicular thyroid cancer (FTC), including oncocytic or Hürthle cell carcinoma:
- pT1b-2 (≤4cm) irrespective of molecular genetic markers
- Minimally invasive, with capsular invasion +/- minimal (≤4 foci) vascular invasion (the latter is now called encapsulated angioinvasive and is at the discretion of the MDT)
- Confined to thyroid or minimal extrathyroidal extension
- Aged 16 or over
- 'low risk' differentiated thyroid cancer confirmed by cytology or core biopsy.
- cT1b-2 irrespective of molecular genetic markers
- cN0
- Contralateral lobe without suspicious nodule(s) (U2, or U3/U4 with Thy2 on FNAC)
Who cannot join
- >4cm
- unifocal pT1a (≤1cm) PTC or FTC (unless pN1a as above)
- NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features)
- Anaplastic, poorly differentiated or medullary thyroid carcinoma
- R2
- gross extrathyroidal extension
Show all 22Show fewer
- pT4 or macroscopic tumour invasion of loco-regional tissues or structures
- pN1a with >5 foci or extranodal spread
- pN1b
- M1
- Aggressive PTC with any of the following features:
- Widely invasive
- Poorly differentiated
- Anaplastic
- predominance of Tall cell, Columnar cell, Hobnail, Diffuse sclerosing and other higher risk variants
- FTC, including oncocytic or Hürthle cell cancer with any of the following features:
- Minimally invasive with extensive vascular invasion (now called encapsulated angioinvasive) (>4 foci)
- Widely invasive
- Poorly differentiated
- Anaplastic
- Group 2 (DTC on cytology or after core biopsy, who has not had prior thyroid surgery yet)
- M1
Trial locations and contacts
33 sites in 1 country. Contact the study team or a site near you to ask about taking part.
33 sites in 1 country
United Kingdom33 sites, 33 recruiting
- Not yet recruiting
Royal United Hospital
Bath
Andrew Carswell
- Recruiting
Queen Elizabeth Hospital
Birmingham
Neil Sharma
- Recruiting
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol
Oliver Dale
- Recruiting
Addenbrooke's Hospital
Cambridge
Brian Fish
- Recruiting
University Hospital of Wales
Cardiff
Michael Stechman
- Recruiting
Colchester Hospital
Colchester
Abdul Qureshi
- Recruiting
Leighton Hospital
Crewe, Cheshire, CW1 4QJ
Eriola Mushi
- Recruiting
Royal Derby Hospital
Derby
Hazem Nijim
- Recruiting
Ninewells Hospital
Dundee
Jaiganesh Manickavasagam
- Recruiting
NHS Lothian
Edinburgh
Iain Nixon
- Recruiting
Royal Devon and Exeter Hospital
Exeter
Joel Smith
- Recruiting
Forth Valley Royal Hospital
Falkirk
Michail Winkler
- Recruiting
Medway Maritime Hospital
Gillingham
Maria Acosta
- Recruiting
NHS Greater Glasgow & Clyde
Glasgow
Catriona Douglas
- Recruiting
Ipswich Hospital
Ipswich
Billy Wong
- Recruiting
Leicester Royal Infirmary
Leicester
Oladejo Olaleye
- Recruiting
Liverpool University Hospitals
Liverpool
Christopher Loh
- Recruiting
Guy's Hospital
London
Ricard Simo
- Recruiting
Lister Hospital
London
George Mochloulis
- Recruiting
Northwick Park Hospital
London
Zi Wei Liu
- Recruiting
St George's Hospital
London
Enyinnaya Ofo
- Recruiting
The Royal Marsden Hospitals
London
Vinidh Paleri
- Not yet recruiting
University College London Hospital
London
Tarek Abdel-Aziz
- Recruiting
Luton and Dunstable University Hospital
Luton
Tarun Sood
- Recruiting
Northampton General Hospital
Northampton
Rohan Bidaye
- Recruiting
Norfolk and Norwich University Hospital
Norwich
Ramez Nassif
- Not yet recruiting
Nottingham University Hospitals NHS Trust
Nottingham
Neeraj Sethi
- Recruiting
Derriford Hospital
Plymouth
Richard Williams
- Recruiting
University Hospitals Dorset NHS Foundation Trust
Poole
Neil De Zoysa
- Recruiting
Queen Alexandra Hospital
Portsmouth
Costa Repanos
- Recruiting
Glan Clwyd Hospital (Betsi Cadwaladr University Health Board)
Rhyl
Kym Best
- Recruiting
Sheffield Teaching Hospitals
Sheffield
Saba Balasubramanian
- Recruiting
Musgrove Park Hospital
Taunton
Edward Chisholm
About this study
This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer.
Patients will be identified via oncology multidisciplinary team meetings. There will be two sources of patients in the trial, with the same histological diagnoses and prognosis (i.e. recurrence risk):
Read more
- Group 1: Patients who have already had a HT for thyroid problems and are then subsequently diagnosed with low risk DTC will be randomised 1:1 to undergo surveillance only OR a second operation to remove the rest of their thyroid gland (two-stage total thyroidectomy).
- Group 2: Patients diagnosed with low risk DTC using cytology (Thy5) but no surgery performed will be randomised 1:1 to have either a hemi-thyroidectomy OR a single-stage total thyroidectomy.
The overall aim of the trial is to determine whether hemithyroidectomy is an acceptable and cost-effective surgical procedure compared to total thyroidectomy in low risk thyroid cancer. Overall, 456 patients will be recruited to the trial. Patients will be initially be followed up post-surgery then 12 monthly for 6 years.
- Conditions
- Differentiated Thyroid Cancer
- Being tested
- Total Thyroidectomy, Hemithyroidectomy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total ThyroidectomyProcedure or surgery
Total Thyroidectomy - surgical removal of entire thyroid gland
HemithyroidectomyProcedure or surgery
Hemithyroidectomy - surgical removal of partial thyroid gland
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Two-stage Completion Thyroidectomy | Active comparator | Patients randomised to this arm will undergo a 2nd operation to remove the remaining thyroid lobe. Receives: Procedure: Total Thyroidectomy |
| Group 1: Surveillance | No intervention | Patients randomised to this arm will have no 2nd surgery and proceed directly to follow-up visits. |
| Group 2: Hemi-thyroidectomy | Experimental | Patients randomised to this arm will have a single HT operation to remove thyroid lobe with the tumour. Receives: Procedure: Hemithyroidectomy |
| Group 2: Total Thyroidectomy | Active comparator | Patients randomised to this arm will have a single TT operation to remove the entire thyroid gland. Receives: Procedure: Total Thyroidectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
3 Year Recurrence Rate
(defined as thyroid cancer recurrence, metastatic disease or death from thyroid cancer (whichever occurs first))
Measured: From surgery to any signs or symptoms of the cancer or death assessed up to a maximum of 3 years from surgery date
Secondary outcomes (17)
5 Year Recurrence Rate
(defined as thyroid cancer recurrence, metastatic disease or death from thyroid cancer (whichever occurs first))
Measured: From surgery to any signs or symptoms of the cancer or death assessed up to a maximum of 5 years from surgery date
Anatomical Site of Recurrence
Location of recurrence
Measured: From surgery to confirmed recurrence assessed up to a maximum of 5 years from surgery date
Risk of Loco-Regional Recurrence
(based on time to recurrence in the neck only)
Measured: From surgery to confirmed recurrence assessed up to a maximum of 5 years from surgery date
Number of Additional Investigations and Procedures after Surgery
Number of further investigations/procedures related to the patient's thyroid surgery or thyroid cancer e.g. imaging, blood test, biopsy etc.
Measured: 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery
Type of Additional Investigations and Procedures after Surgery
Type of further investigations/procedures related to the patient's thyroid surgery or thyroid cancer e.g. imaging, blood test, biopsy etc.
Measured: 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery
Voice Function
Measured using the Voice Handicap Index questionnaire (VHI-10); scores range from 0-40 with higher scores indicating greater voice-related handicap
Measured: Surgical complications and severity: From surgery date to discharge, 2-4 weeks, 6 months and 18 months from date of surgery; Voice Function: Post-randomisation/pre-surgery, 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Surgical complications and severity
Using CTCAE v5.0 and the highest grade of each event type for each patient
Measured: Surgical complications and severity: From surgery date to discharge, 2-4 weeks, 6 months and 18 months from date of surgery; Voice Function: Post-randomisation/pre-surgery, 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Requirement for Hormone Replacement Therapy
(percentage of patients who require this therapy compared between the trial arms)
Measured: From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (EORTC QLQ-C30)
Measured using EORTC QLQ-C30; Scales range from 0-100 with higher scores for the functioning scales and global health status indicating higher QoL and higher scores on the symptom and single-item scales indicating lower QoL
Measured: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (EORTC QLQ-THY35)
Measured using EORTC QLQ-THY35; Scales range from 0-100 with higher scores indicating higher QoL and lower scores indicating lower QoL
Measured: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (EQ-5D-5L)
Measured using EQ-5D-5L; EQVAS score ranges from 0-100 with higher scores indicating higher QoL and lower scores indicating lower QoL; EQ-5D-5L index scores range from -0.224-1 with higher scores indicating higher QoL and lower scores indicating lower QoL
Measured: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (FoP-Q-SF)
Measured using FoP-Q-SF; scores range from 12-60 with higher scores indicating lower QoL and lower scores indicating higher QoL
Measured: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Cost and Health Resource Use (EQ-5D-5L)
Measured using EQ-5D-5L (generic QoL)
Measured: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Cost and Health Resource Use (EORTC QLQ-C30)
Measured using EORTC QLQ-C30 (cancer-specific QoL)
Measured: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Cost and Health Resource Use (EORTC QLQ-THY34)
Measured using EORTC QLQ-THY34 (Cancer site specific QoL)
Measured: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Secondary Care Health Resource Use
Collected using eCRFs and retrospectively for the study period from data in the Hospital Episodes Statistics linked to records in the NCRAS
Measured: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Primary Care Health Resource Use
Collected using eCRFs (Review of Primary Care Visits)
Measured: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2022
- Study start14 Feb 2022
- Primary completion31 Jul 2028 (estimated)
- Study completion31 Jul 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Differentiated Thyroid CancerStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 456 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- Responsible party
- Sponsor
- Investigators
- Dae Kim, Principal investigator, The Royal Marsden Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05604963
- Sponsor's protocol ID
- UCL/136591
- Acronym
- HoT
- Status last verified
- Mar 2026
- First submitted
- 22 Jul 2022
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
- ClinicalTrials.gov ID
- NCT05604963
- Acronym / sponsor ID
- HoT / UCL/136591
- Conditions
- Differentiated Thyroid Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 456 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- Study start
- 14 Feb 2022 (actual)
- Primary completion
- 31 Jul 2028 (estimated)
- Study completion
- 31 Jul 2031 (estimated)
- First posted
- 3 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer.
Patients will be identified via oncology multidisciplinary team meetings. There will be two sources of patients in the trial, with the same histological diagnoses and prognosis (i.e. recurrence risk):
- Group 1: Patients who have already had a HT for thyroid problems and are then subsequently diagnosed with low risk DTC will be randomised 1:1 to undergo surveillance only OR a second operation to remove the rest of their thyroid gland (two-stage total thyroidectomy).
- Group 2: Patients diagnosed with low risk DTC using cytology (Thy5) but no surgery performed will be randomised 1:1 to have either a hemi-thyroidectomy OR a single-stage total thyroidectomy.
The overall aim of the trial is to determine whether hemithyroidectomy is an acceptable and cost-effective surgical procedure compared to total thyroidectomy in low risk thyroid cancer. Overall, 456 patients will be recruited to the trial. Patients will be initially be followed up post-surgery then 12 monthly for 6 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1: Two-stage Completion Thyroidectomy | Active comparator | Procedure: Total ThyroidectomyPatients randomised to this arm will undergo a 2nd operation to remove the remaining thyroid lobe. |
| Group 1: Surveillance | No intervention | –Patients randomised to this arm will have no 2nd surgery and proceed directly to follow-up visits. |
| Group 2: Hemi-thyroidectomy | Experimental | Procedure: HemithyroidectomyPatients randomised to this arm will have a single HT operation to remove thyroid lobe with the tumour. |
| Group 2: Total Thyroidectomy | Active comparator | Procedure: Total ThyroidectomyPatients randomised to this arm will have a single TT operation to remove the entire thyroid gland. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (21 listed)
- Aged 16 or over
- pT1b-2 (≤4cm) irrespective of molecular genetic markers
- R0 resection (clinically excised but microscopic R1 resected tumours at discretion of the local MDT)
- cN0 or pN0, pNX \& pN1a (≤5 foci, no extranodal spread)
- Confined to thyroid or minimal extrathyroidal extension
Key exclusion criteria (22 listed)
- >4cm
- unifocal pT1a (≤1cm) PTC or FTC (unless pN1a as above)
- NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features)
- Anaplastic, poorly differentiated or medullary thyroid carcinoma
- R2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total ThyroidectomyTotal Thyroidectomy - surgical removal of entire thyroid gland | Procedure or surgery | Group 1: Two-stage Completion Thyroidectomy, Group 2: Total Thyroidectomy |
| HemithyroidectomyHemithyroidectomy - surgical removal of partial thyroid gland | Procedure or surgery | Group 2: Hemi-thyroidectomy |
Primary outcome
3 Year Recurrence Rate
Time frame: From surgery to any signs or symptoms of the cancer or death assessed up to a maximum of 3 years from surgery date
(defined as thyroid cancer recurrence, metastatic disease or death from thyroid cancer (whichever occurs first))
17 secondary outcomes
5 Year Recurrence Rate
Time frame: From surgery to any signs or symptoms of the cancer or death assessed up to a maximum of 5 years from surgery date
Anatomical Site of Recurrence
Time frame: From surgery to confirmed recurrence assessed up to a maximum of 5 years from surgery date
Risk of Loco-Regional Recurrence
Time frame: From surgery to confirmed recurrence assessed up to a maximum of 5 years from surgery date
Number of Additional Investigations and Procedures after Surgery
Time frame: 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery
Type of Additional Investigations and Procedures after Surgery
Time frame: 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery
Voice Function
Time frame: Surgical complications and severity: From surgery date to discharge, 2-4 weeks, 6 months and 18 months from date of surgery; Voice Function: Post-randomisation/pre-surgery, 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Surgical complications and severity
Time frame: Surgical complications and severity: From surgery date to discharge, 2-4 weeks, 6 months and 18 months from date of surgery; Voice Function: Post-randomisation/pre-surgery, 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Requirement for Hormone Replacement Therapy
Time frame: From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (EORTC QLQ-C30)
Time frame: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (EORTC QLQ-THY35)
Time frame: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (EQ-5D-5L)
Time frame: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Health Related Quality of Life (FoP-Q-SF)
Time frame: Baseline (post-randomisation/pre-surgery), 2-4 weeks and 6, 18, 30, 42, 54, 66 and 78 months from date of surgery.
Cost and Health Resource Use (EQ-5D-5L)
Time frame: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Cost and Health Resource Use (EORTC QLQ-C30)
Time frame: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Cost and Health Resource Use (EORTC QLQ-THY34)
Time frame: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Secondary Care Health Resource Use
Time frame: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Primary Care Health Resource Use
Time frame: a. Baseline, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. b. From surgery date to discharge, 2-4 weeks and 6, 18, 30, 42, 54, 66 & 78 months from date of surgery. c/d. 6, 18, 30, 42, 54, 66 & 78 months from date of surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Differentiated Thyroid Cancer
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
RecruitingPhase 1
Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer
Enrolling by invitationPhase 3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cancer, Renal Cell Carcinoma (RCC)
RecruitingPhase 2
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer, Pediatric Cancer
Active, not recruitingPhase 3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Differentiated Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dae Kim principal investigator
The Royal Marsden Hospital
33 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Total Thyroidectomy and Hemithyroidectomy in people with Differentiated Thyroid Cancer, run by University College, London at 33 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 33 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jeannie Chamberlain (020 3108 4875, ctc.hot@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
3 Year Recurrence Rate (time frame: From surgery to any signs or symptoms of the cancer or death assessed up to a maximum of 3 years from surgery date). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026; AzTrials last refreshed its copy on 30 Oct 2026.